They can be used as first-line agents for obese PCOS patients with mild-to-moderate features of oligoanovulation and/or infertility. They can be used as add-on therapy to antiandrogens for greater efficacy. Their beneficial role in metabolic syndrome gives them an upper edge to be used in preference to oral contraceptives in PCOS patients. Data with glitazones is limited and owing to their weight gaining tendency, they are not preferred.